Skip to main content

A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.

Publication ,  Conference
Liu, JF; Brady, MF; Matulonis, UA; Miller, A; Kohn, EC; Swisher, EM; Tew, WP; Cloven, NG; Muller, C; Bender, D; Moore, RG; Michelin, DP ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
2020

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

2020

Volume

38

Issue

15

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Liu, J. F., Brady, M. F., Matulonis, U. A., Miller, A., Kohn, E. C., Swisher, E. M., … Bookman, M. A. (2020). A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).
Liu, Joyce F., Mark F. Brady, Ursula A. Matulonis, Austin Miller, Elise C. Kohn, Elizabeth M. Swisher, William P. Tew, et al. “A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.
Liu JF, Brady MF, Matulonis UA, Miller A, Kohn EC, Swisher EM, Tew WP, Cloven NG, Muller C, Bender D, Moore RG, Michelin DP, Waggoner SE, Geller MA, Fujiwara K, D’Andre SD, Carney M, Secord AA, Moxley KM, Bookman MA. A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer. JOURNAL OF CLINICAL ONCOLOGY. 2020.

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

2020

Volume

38

Issue

15

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences